ZENITH study shows sotatercept is effective for PAH patients at high risk of mortality

PHA Canada
Nov 26, 2024
1 min read

The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or hospitalizations for pulmonary arterial hypertension (PA) in PAH patients in functional class III or IV at high risk of mortality. Because of its "overwhelming efficacy," the trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here.

Recent Posts

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

Comments